

- Lymphohistiocytosis, hemophagocytic, 375e-2, 2112
- Lymphoid hyperplasia  
atypical, 710  
cutaneous (pseudolymphoma), 353–354, 364t, 366
- Lymphoid malignancies, **135e-1, 695**. *See also* Leukemia  
anemia in, 393  
approach to the patient, 699–701  
AV conduction block in, 1471t  
B cell  
  B-cell prolymphocytic lymphoma, 135e-2t, 706  
  Burkitt's lymphoma. *See* Burkitt's lymphoma  
  chronic lymphoid leukemia. *See* B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma  
  diffuse large B-cell lymphoma. *See* Diffuse large B-cell lymphoma  
  follicular lymphoma. *See* Follicular lymphoma  
  hairy cell leukemia. *See* Hairy cell leukemia  
  intravascular large B-cell lymphoma, 135e-2  
  lymphomatoid granulomatosis, 135e-3  
  MALT lymphoma. *See* Mucosa-associated lymphoid tissue (MALT) lymphoma  
  mantle cell lymphoma. *See* Mantle cell lymphoma  
  mediastinal (thymic) large B-cell lymphoma, 135e-2  
  nodal marginal zone B-cell lymphoma, 135e-2, 707  
  precursor B-cell lymphoblastic, 701  
  primary effusion lymphoma, 135e-2, 214e-7, 1194, 1270  
  splenic marginal zone lymphoma, 135e-1, 135e-2t, 706  
  carcinoma of unknown primary and, 120e-2t  
  classification of, 135e-1t, 695, 695t, 696t  
  CNS, primary. *See* Primary central nervous system lymphoma (PCNSL)  
  deaths from, 467t, 470t  
  definition of, 102e-1  
  diseases or exposures associated with, 697t  
  EBV infection and, 135e-3, 135e-4, 697, 697t, 1188–1189  
  epidemiology of, 695–697, 695f  
  erythrophagocytosis in, 81e-11f  
  etiology of, 695–697, 697t, 1188–1189  
  fever in, 126  
  gene profiling in, 699  
  genetic considerations in, 101e-2t, 101e-3t, 698–699, 699t  
  in HIV infection, 1270–1271, 1271f  
  Hodgkin's lymphoma. *See* Hodgkin's lymphoma  
  immunology of, 697–699, 698f  
  incidence of, 467t  
  infections in, 488  
  liver disease in, 367e-3  
  lymphadenopathy in, 408  
  neuropathy in, 2685  
  NK cell  
    blastic, 135e-4  
    extranodal NK/T cell, nasal type, 135e-3, 697, 708  
  nodular follicular, 81e-7f  
  ocular invasion by, 206  
  oral manifestations of, 239t, 1271f  
  paraneoplastic syndromes in, 608, 609t, 612t, 618–619  
  pleural effusion in, 474  
  proteinuria in, 293  
  in rheumatoid arthritis, 2138  
  in Sjögren's syndrome, 2167, 2167t  
  skin manifestations of, 76e-5f, 353, 353t, 2193  
  small intestinal, 537  
  splenomegaly in, 411  
  T cell  
    adult. *See* Adult T-cell leukemia/lymphoma  
    anaplastic large T/null cell lymphoma, 102e-5t, 699t, 702t, 707–708  
    angiimmunoblastic T-cell lymphoma, 135e-4 to 135e-5, 708  
    enteropathy-type lymphoma, 135e-3, 708  
    extranodal T/NK cell lymphoma, nasal type, 135e-3, 697, 708, 2184  
    hepatosplenic  $\gamma\delta$  T-cell lymphoma, 135e-3, 708  
    mycosis fungoides. *See* Mycosis fungoides; Mycosis fungoides (cutaneous T-cell lymphoma)  
    precursor T-cell lymphoblastic lymphoma/leukemia, 702t, 707  
    primary cutaneous CD30+ T-cell lymphoma, 135e-4  
    subcutaneous panniculitis-like T-cell lymphoma, 135e-4, 708  
  in thymus, 123e-1. *See also* Thymoma  
  in thyroid, 2307  
  treatment of, 102e-3, 102e-5t  
  tumor markers in, 473t  
  urticaria in, 135
- Lymphoid tissue, mucosa-associated. *See* Mucosa-associated lymphoid tissue (MALT)
- Lymphoma. *See* Lymphoid malignancies
- Lymphoma cutis, 364t, 366, 367
- Lymphoma-like disorders, 710
- Lymphomatoid granulomatosis, 135e-3, 1716, 2184
- Lymphomatoid papulosis, 710
- Lymphoocclusive bandage, for snakebite, 2735
- Lymphoplasmacytic lymphoma, 706–707
- Lymphoplasmacytic sclerosing pancreatitis. *See* IgG4-related disease (IgG4-RD)
- Lymphoscintigraphy, 1654
- Lymphotactin/SCM-1, 372e-11t
- Lyn, 2115
- Lynch's syndrome. *See* Hereditary nonpolyposis colon cancer
- Lyonization, 735
- Lysergic acid diethylamide (LSD), 469e-4
- Lysine metabolism disorders, 434e-3t
- Lysinuric protein intolerance (dibasic aminoaciduria), 332e-7t, 435e-1t, 435e-2
- Lysosomal acid lipase deficiency (cholesteryl ester storage disease), 432e-4t, 432e-5, 2443
- Lysosomal storage diseases, **432e-1**  
  genetic considerations in, 432e-1  
  glycogen disorders, 432e-4t. *See also* Pompe disease (acid  $\alpha$ -1,4 glucosidase deficiency)  
  glycoproteinoses, 432e-3t  
  GM<sub>2</sub> gangliosidosis, 432e-3t. *See also* Tay-Sachs disease  
  leukodystrophies, 432e-4t  
  mucopolysaccharidosis, 432e-3t  
  mucopolysaccharidosis, 432e-2t, 432e-5–6, 436e-5f  
  neutral glycosphingolipidoses. *See* Fabry's disease; Gaucher's disease; Niemann-Pick disease  
  neutral lipid disorders, 432e-4t  
  pathogenesis of, 432e-1
- Lysosome(s), 94e-3, 432e-1
- Lysaviruses, 1299, 1304. *See also* Rabies
- M**
- Machado-Joseph disease (SCA3), 440t, 451e-1t, 2628–2629
- Machine operator's lung, 1681t
- Machupo/Bolivian hemorrhagic fever, 1320
- Machupo virus, 1306t
- Maciel virus, 1308t
- MAC infections. *See* *Mycobacterium avium* complex (MAC) infections
- Macitentan, 1659–1660, 1660t
- MACOP-B regimen, 135e-2
- Macroalbuminuria, 1616, 2425, 2425f
- Macroamylasemia, 2102
- Macrocytosis, 81e-3f, 393, 395f, 2067
- Macroglossia, 241t, 721, 721f
- Macrolides  
  action of, 931, 931t, 942  
  adverse effects of, 938t, 943  
  drug interactions of, 939t  
  indications for, 943  
  resistance to  
    in *M. pneumoniae*, 1164  
    manifestations of, 807  
    mechanisms of, 931t, 934  
    in pneumococci, 807  
    prevalence of, 966  
    prevention of, 230  
    in *S. pyogenes*, 233  
    in *T. pallidum*, 1138
- Macroovalocytes, 81e-3f
- Macrophage(s)  
  in adaptive immunity, 372e-7t, 372e-9f  
  in asthma, 1672  
  functions of, 421  
  in HIV infection, 1238  
  in innate immunity, 372e-4, 372e-6, 372e-7t, 372e-14f  
  in pneumonia, 804  
  in shock, 1747  
  in smokers, 1701  
  in tuberculosis, 1106–1107
- Macrophage colony-stimulating factor (M-CSF), 372e-11t
- Macrophage-derived chemokine. *See* MDC (CCL22)
- Macrophage inflammatory protein, 416
- Macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ), 372e-12t
- Macrophage inflammatory protein-1 $\beta$  (MIP-1 $\beta$ ), 372e-12t
- Macrothrombocytopenia, 726f
- Macula  
  anatomy of, 195  
  cherry red spot, 40e-4, 40e-4f  
  damage to, 197  
  normal, 40e-1, 40e-1f
- Macula densa, 332e-2, 332e-2f
- Maculae ceruleae, 2746
- Macular degeneration  
  diagnosis of, 205, 205f  
  dry (nonexudative), 205  
  gene therapy for, 91e-3  
  pathogenesis of, 205  
  prevention of, 96e-7  
  treatment of, 205  
  visual loss in, 205  
  wet (exudative), 205
- Macular hole, 206
- Maculatum disease, 1155t
- Macules, 127, 240t, 339t, 340f
- Madrid virus, 1309t
- Madurella, 1355
- Mafenide acetate, 166e-3, 262e-4
- Maffucci's syndrome, 367, 426e-7, 594
- MAG (myelin-associated glycoprotein), 372e-24t, 444e-8, 718
- Maggots, 2747
- Magic mint (*Salvia divinorum*), 469e-4
- MAGIC syndrome, 2204
- Magnesium  
  deficiency of. *See* Hypomagnesemia  
  excess of. *See* Hypermagnesemia  
  metabolism of, 2461  
  parenteral requirement for, 98e-5t  
  recommended intake of, 95e-3t  
  reference values for, 2761t  
  renal transport of, 332e-4f, 332e-8  
  supplements, 216, 2497
- Magnesium citrate, 62t
- Magnesium hydroxide, 62t, 1920, 1970t
- Magnesium sulfate  
  for asthma exacerbations, 1679  
  for cardiac arrest, 1769f  
  for eclamptic seizures, 46  
  for sedation in tetanus, 986
- Magnesium-wasting syndromes, 2461–2462, 2462t
- Magnetic resonance angiography (MRA)  
  in frostbite, 478e-5  
  in neurologic disease, 440e-6–8, 441e-16f  
  in peripheral artery disease, 1643, 1644f  
  phase-contrast, 440e-7